+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Viral Vector Purification / Virus Purification Products Market (kit, prepacked column, resin, cassette, filter plate, capsule, reagent and others), 2020-2030

  • ID: 5093931
  • Report
  • May 2020
  • Region: Global
  • 275 Pages
  • Roots Analysis
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • 4D Molecular Therapeutics
  • BIA Separations
  • Errant Gene Therapeutics
  • Juno Therapeutics
  • ORCA Therapeutics
  • Solid Biosciences
  • MORE

Overview

Since the approval and launch of cell and gene therapy products, such as Zolgensma® (2019), ZYNTEGLO™ (2019), Luxturna® (2017), KYMRIAH® (2017) and YESCARTA® (2017), there has been a significant increase in demand for viral vectors. Experts believe that the number of such therapies is likely to double over the next couple of years. It is also worth mentioning that this particular field of medical research received close to USD 10 billion in funding in 2019.

Currently, over 1,000 cell and gene therapy-related clinical trials are being conducted, worldwide. Genetic manipulation is a basic requirement of cell and gene therapy development, and, as a result, gene delivery vectors are considered to be of utmost importance in this domain. So far, viral vectors (such as those based on adeno-associated viruses (AAV), adenoviruses, lentivirus, retroviruses and other viruses) have been shown to be the most versatile gene delivery tools available, having demonstrated high transfection efficiencies in both preclinical and clinical settings. Further, taking into account the therapeutic efficacy and low side effects profiles of cell and gene therapies, the demand for such interventions is anticipated to grow at a rapid pace, resulting in a proportional increase in need for appropriate vector systems, as well. However, viral vector development and manufacturing is a complex and cost intensive process. One of the primary concerns associated with viral vector production is related to yield; in fact, a singular batch run is estimated to incur losses of up to 70% during the purification step alone.  

A number of techniques are presently used for viral vector purification. Over the years, size-based viral purification strategies, such as density-gradient ultracentrifugation, ultrafiltration, precipitation and size-exclusion chromatography (SEC), have become part of the accepted industry standard. However, recently, stakeholders have begun relying more on affinity chromatography-based purification regimens, given its robustness and high selectivity. Presently, several companies claim to offer a diverse range of virus purification solutions, including, filter plates, prepacked chromatography columns and resins, and consolidated kits, for viral vector (virus) purification. As indicated earlier, downstream processing of viral vector products is challenging.

Existing separation and purification techniques are not efficient when it comes to purifying viral vectors at large scales. Moreover, these techniques are often unable to separate complete viruses from empty capsids, thereby, compromising product recovery. Therefore, it has become essential for stakeholders to develop innovative ways to optimize the purification process, in order to further improve virus recovery and facilitate effective removal of contaminants/impurities. Currently, the viral vector purification products market is driven by the abovementioned surge in demand for viral vectors. In this context, it is worth mentioning that there are several virus based vaccines under development against the novel SARS-CoV-2 coronavirus strain. In fact, according to the WHO, there are over 20 viral vaccines currently being investigated against the novel coronavirus. Developing the means to better purify viruses is, therefore, likely to significantly impact viable vaccine yield. The current crisis is definitely going to have a strong impact on the virus purification products market.

Scope of the Report

The ‘Viral Vector Purification  / Virus Purification Products Market (kit, prepacked column, resin, cassette, filter plate, capsule, reagent and others), 2020-2030’ report features an extensive study of various products available for viral vector purification, in addition to the current market landscape and future potential of product developers.

Amongst other elements, the report features:

An overview of the current market landscape of companies providing products for purification of viruses / viral vectors, using different techniques, such as chromatography, centrifugation and filtration. It features information on the type of product (kit, prepacked column, resin, cassette, filter plate, capsule and reagent), type of purification technique (chromatography, centrifugation and filtration),  scale of operation (lab-scale, clinical and commercial), type of viral vector (AAV, adenovirus, lentivirus, retrovirus and others) and details on other physical and operational parameters of the product (such as matrix, pore size, volume of bed, flow rate, operating pressure, working temperature, pH, filtration area and process time). In addition, the chapter includes information on the purification product developers, including details on the year of establishment, company size and location of headquarters.
Elaborate profiles of key players, including an overview of the company, product portfolio (viral vector purification products), recent developments and an informed future outlook.  
An analysis evaluating the potential strategic partners (comprising of viral vector-based therapy developers and viral vector manufacturers) for viral vector purification product developers, based on several parameters, such as type of viral vector,  developer strength, operational strength, therapeutic area, strength of clinical pipeline and strength of preclinical pipeline.
A clinical trial analysis of completed, ongoing and planned studies of various viral vector-based cell therapies, gene therapies and vaccines (approved / under development). It features detailed analyses of clinical studies of different viral-vector based therapies on the basis of their registration year, phase of development, trial status, type of therapy, therapeutic area, type of sponsor/collaborator, geographical location, number of patients enrolled and key players.
An informed estimate of the annual clinical and commercial demand (in terms of number of patients) for viral vectors, taking into account the marketed gene-based therapies and clinical studies evaluating vector-based therapies; the analysis also takes into consideration various relevant parameters, such as target patient population, dosing frequency and dose strength. Further, the demand has been segregated on the basis of type of viral vector, type of therapy, therapeutic are and geographical location.
A case study on tangential flow filtration (TFF), highlighting the role, advantages and disadvantages of the technique for purification of viral vectors; the chapter features details of products used for TFF, including product type, scale of operation, membrane material, flow rate and filtration area.
A case study featuring the viral vector manufacturers providing commercial scale production, highlighting details on their year of establishment, company size, type of viral vector (AAV, adenovirus, lentivirus, retrovirus and others), purpose of production (in-house and contract-basis), and location of headquarters and manufacturing facilities.

One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for viral vector purification product developers, over the coming decade. Based on various parameters, such as the likely increase in number of clinical studies related to viral vector-based therapies, anticipated growth in target patient population, existing price variations across different purification techniques, and the success of cell and gene therapy products (considering both approved and late-stage clinical candidates), we have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2020-2030. In order to provide a detailed future outlook, our projections have been segmented on the basis of [A] type of viral vector (AAV, adenovirus, lentivirus, retrovirus and others), [B] type of purification technique (chromatography, centrifugation and filtration), [C] type of therapy (gene therapy, cell therapy and viral vaccines) [D] therapeutic area (oncological disorders, cardiovascular disorders, ophthalmic disorders, metabolic disorders, inflammation & immunological diseases and others), [E] scale of operation (preclinical/clinical and commercial) and [F] key geographical regions (North America, Europe, Asia Pacific and rest of the world).

The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. The opinions and insights presented in the report were influenced by discussions held with several players in this industry. The study includes detailed transcripts of discussions held with the following individuals:

  • Haifeng Chen (Chief Executive Officer, Virovek)
  • Jeffrey Hung (Chief Commercial Officer, Vigene Biosciences)
  • Kai Lipinski (Chief Scientific Officer, Vibalogics)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • 4D Molecular Therapeutics
  • BIA Separations
  • Errant Gene Therapeutics
  • Juno Therapeutics
  • ORCA Therapeutics
  • Solid Biosciences
  • MORE

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Viral and Non-Viral Methods of Gene Transfer
3.3. Viral Vectors for Genetically Modified Therapies
3.4. Types of Viral Vectors
3.4.1. Adeno-associated Viral Vectors
3.4.2. Adenoviral Vectors
3.4.3. Lentiviral Vectors
3.4.4. Retroviral Vectors
3.4.5. Other Viral Vectors
3.4.5.1. Alphavirus
3.4.5.2. Foamy Virus
3.4.5.3. Herpes Simplex Virus
3.4.5.4. Sendai Virus
3.4.5.5. Simian Virus
3.4.5.6. Vaccinia Virus
3.6. Applications of Viral Vectors
3.6.1. Cell and Gene Therapy
3.6.1. Vaccinology
3.7. Current Trends in Vector Development / Manufacturing
3.7.1. Vector Engineering
3.7.2. Cargo Engineering
3.8. Vector Manufacturing
3.8.1. Types of Vector Manufacturers
3.8.2. Viral Vector Manufacturing Process
3.8.3. Challenges Related to Vector Manufacturing
3.8.3.1. Vector Purification Process
3.8.3.2. Techniques Used for Vector Purification
3.8.3.2.1. Centrifugation and Ultra-Centrifugation
3.8.3.2.2. Filtration
3.8.3.2.3. Chromatography
3.8.3.3. Challenges Related to Vector Purification
3.9. Future of Vector Purification

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Viral Vector Purification Products: Overall Market Landscape
4.2.1. Analysis by Type of Product
4.2.2. Analysis by Type of Purification Technique
4.2.3. Analysis by Scale of Operation
4.2.5. Analysis by Type of Viral Vector
4.2.6. Viral Vector Purification Products for Chromatography
4.2.6.1. Analysis by Type of Chromatographic Technique
4.2.7. Viral Vector Purification Products for Centrifugation
4.2.8. Viral Vector Purification Products for Filtration
4.3. Viral Vector Purification Product Developers
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Geographical Location

5. COMPANY PROFILES
5.1. Chapter Overview
5.2. Agilent Technologies
5.2.1. Company Overview
5.2.2. Product Portfolio
5.2.3. Recent Developments and Future Outlook
5.3. BIA Separations
5.3.1. Company Overview
5.3.2. Product Portfolio
5.3.3. Recent Developments and Future Outlook
5.4. Bio-Rad Laboratories
5.4.1. Company Overview
5.4.2. Product Portfolio
5.4.3. Recent Developments and Future Outlook
5.5. BioVision
5.5.1. Company Overview
5.5.2. Product Portfolio
5.5.3. Recent Developments and Future Outlook
5.6. Cytiva (formerly GE Lifesciences)
5.6.1. Company Overview
5.6.2. Product Portfolio
5.6.3. Recent Developments and Future Outlook
5.7. Merck
5.7.1. Company Overview
5.7.2. Product Portfolio
5.7.3. Recent Developments and Future Outlook
5.8. Sartorius
5.8.1. Company Overview
5.8.2. Product Portfolio
5.8.3. Recent Developments and Future Outlook
5.9. Takara Bio
5.9.1. Company Overview
5.9.2. Product Portfolio
5.9.3. Recent Developments and Future Outlook
5.10. Thermo Fisher Scientific
5.10.1. Company Overview
5.10.2. Product Portfolio
5.10.3. Recent Developments and Future Outlook

6. STRATEGIC PARTNER ANALYSIS
6.1. Chapter Overview
6.2. Methodology and Key Parameters
6.3. Potential Strategic Partners: Viral Vector-based Therapy Developers
6.3.1. Strategic Partner Analysis: AAV Vector-based Therapy Developers
6.3.1.1. Most Likely Partners
6.3.1.2. Likely Partners
6.3.1.3. Less Likely Partners
6.3.1.4. Least Likely Partners
6.3.2. Strategic Partner Analysis: Adenoviral Vector-based Therapy Developers
6.3.2.1. Most Likely Partners
6.3.2.2. Likely Partners
6.3.2.3. Less Likely Partners
6.3.2.4. Least Likely Partners
6.3.3. Strategic Partner Analysis: Lentiviral Vector-based Therapy Developers
6.3.3.1. Most Likely Partners
6.3.3.2. Likely Partners
6.3.3.3. Less Likely Partners
6.3.3.4. Least Likely Partners
6.3.4. Strategic Partner Analysis: Retroviral Vector-based Therapy Developers
6.3.4.1. Most Likely Partners
6.3.4.2. Likely Partners
6.3.4.3. Less Likely Partners
6.3.4.4. Least Likely Partners
6.3.5. Strategic Partner Analysis: Other Viral Vector-based Therapy Developers
6.3.5.1. Most Likely Partners
6.3.5.2. Likely Partners
6.3.5.3. Less Likely Partners
6.3.5.4. Least Likely Partners
6.4. Potential Strategic Partners: Viral Vector Manufacturers
6.4.1. Strategic Partner Analysis: AAV Vector Manufacturers
6.4.1.1. Most Likely Partners
6.4.1.2. Likely Partners
6.4.1.3. Less Likely Partners
6.4.1.4. Least Likely Partners
6.4.2. Strategic Partner Analysis: Adenoviral Vector Manufacturers
6.4.2.1. Most Likely Partners
6.4.2.2. Likely Partners
6.4.2.3. Less Likely Partners
6.4.2.4. Least Likely Partners
6.4.3. Strategic Partner Analysis: Lentiviral Vector Manufacturers
6.4.3.1. Most Likely Partners
6.4.3.2. Likely Partners
6.4.3.3. Less Likely Partners
6.4.3.4. Least Likely Partners
6.4.4. Strategic Partner Analysis: Retroviral Vector Manufacturers
6.4.4.1. Most Likely Partners
6.4.4.2. Likely Partners
6.4.4.3. Less Likely Partners
6.4.4.4. Least Likely Partners
6.4.5. Strategic Partner Analysis: Other Viral Vector Manufacturers
6.4.5.1. Most Likely Partners
6.4.5.2. Likely Partners
6.4.5.3. Less Likely Partners
6.4.5.4. Least Likely Partners

7. CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Viral Vector based Therapies: Clinical Trial Analysis
7.3.1. Analysis by Trial Registration Year
7.3.2. Analysis by Trial Phase
7.3.3. Analysis by Trial Status
7.3.4. Analysis by Type of Therapy
7.3.5. Analysis by Therapeutic Area
7.3.6. Analysis by Type of Sponsor / Collaborator
7.3.7. Analysis by Geographical Location and Trial Status
7.3.8. Most Active Players: Analysis by Number of Registered Trials
7.3.9. Analysis by Patients Enrolled and Trial Phase
7.3.10. Analysis by Patients Enrolled and Type of Therapy
7.3.11. Analysis by Patients Enrolled and Therapeutic Area
7.3.12. Analysis by Patients Enrolled, Trial Status and Geographical Location
7.4. AAV Vector based Therapies
7.4.1. Analysis by Trial Registration Year
7.4.2. Analysis by Trial Phase
7.4.3. Analysis by Trial Status
7.4.4. Analysis by Type of Therapy
7.4.5. Analysis by Therapeutic Area
7.4.6. Analysis by Type of Sponsor / Collaborator
7.4.7. Analysis by Geographical Location and Trial Status
7.4.8. Most Active Players: Analysis by Number of Registered Trials
7.4.9. Analysis by Patients Enrolled and Trial Phase
7.4.10. Analysis by Patients Enrolled and Type of Therapy
7.4.11. Analysis by Patients Enrolled and Therapeutic Area
7.4.12. Analysis by Patients Enrolled, Trial Status and Geographical Location
7.5. Adenoviral Vector based Therapies
7.5.1. Analysis by Trial Registration Year
7.5.2. Analysis by Trial Phase
7.5.3. Analysis by Trial Status
7.5.4. Analysis by Type of Therapy
7.5.5. Analysis by Therapeutic Area
7.5.6. Analysis by Type of Sponsor / Collaborator
7.5.7. Analysis by Geographical Location and Trial Status
7.5.8. Most Active Players: Analysis by Number of Registered Trials
7.5.9. Analysis by Patients Enrolled and Trial Phase
7.5.10. Analysis by Patients Enrolled and Type of Therapy
7.5.11. Analysis by Patients Enrolled and Therapeutic Area
7.5.12. Analysis by Patients Enrolled, Trial Status and Geographical Location
7.6. Lentiviral Vector based Therapies
7.6.1. Analysis by Trial Registration Year
7.6.2. Analysis by Trial Phase
7.6.3. Analysis by Trial Status
7.6.4. Analysis by Type of Therapy
7.6.5. Analysis by Therapeutic Area
7.6.6. Analysis by Type of Sponsor / Collaborator
7.6.7. Analysis by Geographical Location and Trial Status
7.6.8. Most Active Players: Analysis by Number of Registered Trials
7.6.9. Analysis by Patients Enrolled and Trial Phase
7.6.10. Analysis by Patients Enrolled and Type of Therapy
7.6.11. Analysis by Patients Enrolled and Therapeutic Area
7.6.12. Analysis by Patients Enrolled, Trial Status and Geographical Location
7.7. Retroviral Vector based Therapies
7.7.1. Analysis by Trial Registration Year
7.7.2. Analysis by Trial Phase
7.7.3. Analysis by Trial Status
7.7.4. Analysis by Type of Therapy
7.7.5. Analysis by Therapeutic Area
7.7.6. Analysis by Type of Sponsor / Collaborator
7.7.7. Analysis by Geographical Location and Trial Status
7.7.8. Most Active Players: Analysis by Number of Registered Trials
7.7.9. Analysis by Patients Enrolled and Trial Phase
7.7.10. Analysis by Patients Enrolled and Type of Therapy
7.7.11. Analysis by Patients Enrolled and Therapeutic Area
7.7.12. Analysis by Patients Enrolled, Trial Status and Geographical Location
7.8. Other Viral Vector based Therapies
7.8.1. Analysis by Trial Registration Year
7.8.2. Analysis by Trial Phase
7.8.3. Analysis by Trial Status
7.8.4. Analysis by Type of Therapy
7.8.5. Analysis by Therapeutic Area
7.8.6. Analysis by Type of Sponsor / Collaborator
7.8.7. Analysis by Geographical Location and Trial Status
7.8.8. Most Active Players: Analysis by Number of Registered Trials
7.8.9. Analysis by Patients Enrolled and Trial Phase
7.8.10. Analysis by Patients Enrolled and Type of Therapy
7.8.11. Analysis by Patients Enrolled and Therapeutic Area
7.8.12. Analysis by Patients Enrolled, Trial Status and Geographical Location

8. DEMAND ANALYSIS
8.1. Chapter Overview
8.2. Assumptions and Methodology
8.3. Global, Clinical Demand for Viral Vectors
8.3.1. Analysis by Type of Vector
8.3.2. Analysis by Type of Therapy
8.3.3. Analysis by Therapeutic Area
8.3.4. Analysis by Geographical Location
8.4. Global, Commercial Demand for Viral Vectors
8.4.1. Analysis by Type of Vector
8.4.2. Analysis by Type of Therapy
8.4.3. Analysis by Therapeutic Area
8.4.4. Analysis by Geographical Location

9. CASE STUDY: TANGENTIAL FLOW FILTRATION (TFF)
9.1. Chapter Overview
9.2. Role of TFF in Viral Vector Purification
9.2.1. Advantages of TFF
9.2.2. Disadvantages of TFF
9.3. TFF-related Product Suppliers

10. CASE STUDY: VIRAL VECTOR MANUFACTURERS
10.1. Chapter Overview
10.2. Commercial Scale Viral Vector Manufacturers
10.2.1. Analysis by Year of Establishment
10.2.2. Analysis by Company Size
10.2.3. Analysis by Type of Viral Vector
10.2.4. Analysis by Purpose of Production
10.2.5. Analysis by Geographical Location

11. MARKET SIZING AND OPPORTUNITY ANALYSIS
11.1. Chapter Overview
11.2. Forecast Methodology and Key Assumptions
11.3. Overall Viral Vector Purification Products Market, 2020-2030
11.3.1. Viral Vector Purification Products Market: Distribution by Type of Viral Vector, 2020-2030
11.3.2. Viral Vector Purification Products Market: Distribution by Type of Purification Technique, 2020-2030
11.3.3. Viral Vector Purification Products Market: Distribution by Type of Therapy, 2020-2030
11.3.4. Viral Vector Purification Products Market: Distribution by Therapeutic Area, 2020-2030
11.3.5. Viral Vector Purification Products Market: Distribution by Scale of Operation, 2020-2030
11.3.6. Viral Vector Purification Products Market: Distribution by Geographical Location, 2020-2030
11.4. Viral Vector Purification Products Market for AAV Vectors, 2020-2030
11.4.1. AAV Vector Purification Products Market: Distribution by Type of Purification Technique, 2020-2030
11.4.2. AAV Vector Purification Products Market: Distribution by Type of Therapy, 2020-2030
11.4.3. AAV Vector Purification Products Market: Distribution by Therapeutic Area, 2020-2030
11.4.4. AAV Vector Purification Products Market: Distribution by Scale of Operation, 2020-2030
11.4.5. AAV Vector Purification Products Market: Distribution by Geographical Location, 2020-2030
11.5. Viral Vector Purification Products Market for Adenoviral Vectors, 2020-2030
11.5.1. Adenoviral Vector Purification Products Market: Distribution by Type of Purification Technique, 2020-2030
11.5.2. Adenoviral Vector Purification Products Market: Distribution by Type of Therapy, 2020-2030
11.5.3. Adenoviral Vector Purification Products Market: Distribution by Therapeutic Area, 2020-2030
11.5.4. Adenoviral Vector Purification Products Market: Distribution by Scale of Operation, 2020-2030
11.5.5. Adenoviral Vector Purification Products Market: Distribution by Geographical Location, 2020-2030
11.6. Viral Vector Purification Products Market for Lentiviral Vectors, 2020-2030
11.6.1. Lentiviral Vector Purification Products Market: Distribution by Type of Purification Technique, 2020-2030
11.6.2. Lentiviral Vector Purification Products Market: Distribution by Type of Therapy, 2020-2030
11.6.3. Lentiviral Vector Purification Products Market: Distribution by Therapeutic Area, 2020-2030
11.6.4. Lentiviral Vector Purification Products Market: Distribution by Scale of Operation, 2020-2030
11.6.5. Lentiviral Vector Purification Products Market: Distribution by Geographical Location, 2020-2030
11.7. Viral Vector Purification Products Market for Retroviral Vectors, 2020-2030
11.7.1. Retroviral Vector Purification Products Market: Distribution by Type of Purification Technique, 2020-2030
11.7.2. Retroviral Vector Purification Products Market: Distribution by Type of Therapy, 2020-2030
11.7.3. Retroviral Vector Purification Products Market: Distribution by Therapeutic Area, 2020-2030
11.7.4. Retroviral Vector Purification Products Market: Distribution by Scale of Operation, 2020-2030
11.7.5. Retroviral Vector Purification Products Market: Distribution by Geographical Location, 2020-2030
11.8. Viral Vector Purification Products Market for Other Viral Vectors, 2020-2030
11.8.1. Other Viral Vector Purification Products Market: Distribution by Type of Purification Technique, 2020-2030
11.8.2. Other Viral Vector Purification Products Market: Distribution by Type of Therapy, 2020-2030
11.8.3. Other Viral Vector Purification Products Market: Distribution by Therapeutic Area, 2020-2030
11.8.4. Other Viral Vector Purification Products Market: Distribution by Scale of Operation, 2020-2030
11.8.5. Other Viral Vector Purification Products Market: Distribution by Geographical Location, 2020-2030

12. CONCLUDING REMARKS

13. EXECUTIVE INSIGHTS
13.1. Chapter Overview
13.2. Virovek
13.2.1. Company Snapshot
13.2.2. Interview Transcript: Haifeng Chen, Chief Executive Officer
13.3. Vigene Biosciences
13.3.1. Company Snapshot
13.3.2. Interview Transcript: Jeffrey Hung, Chief Commercial Officer
13.4. Vibalogics
13.4.1. Company Snapshot
13.4.2. Interview Transcript: Kai Lipinski, Chief Scientific Officer

14. APPENDIX 1: TABULATED DATA

Note: Product cover images may vary from those shown
3 of 4
  • 4D Molecular Therapeutics
  • Abbott
  • Abeona Therapeutics
  • Actus Therapeutics
  • Adaptimmune Therapeutics
  • Addgene
  • Advanced BioScience Laboratories
  • Advantagene
  • Advaxis
  • Advent
  • Adverum Biotechnologies
  • Agilent Technologies
  • Allergan
  • Allife Medical Science and Technology
  • Allogene Therapeutics
  • AlphaVax
  • ALSTEMlstem
  • Altor BioScience
  • American Gene Technologies
  • Amgen
  • Amicus Therapeutics
  • AMSBIO
  • Anaeropharma Science
  • Angionetics
  • apceth Biopharma
  • Apic Bio
  • Applied Biological Materials
  • Applied Genetic Technologies Corporation
  • Applied Viromics
  • Arthrogen
  • Aruvant Sciences
  • Asklepios BioPharmaceutical
  • Atara Biotherapeutics
  • ATVIO Biotechnology
  • Audentes Therapeutics
  • Aurora Biopharma
  • Autolus
  • AVROBIO
  • Axovant
  • Batavia Biosciences
  • Bayer
  • Baylor College of Medicine
  • Beijing Biohealthcare Biotechnology
  • Beijing Doing Biomedical
  • Beijing Immunochina Medical Science & Technology
  • Beijing Mario Biotech
  • Beijing Sanwater Biological Technology
  • Bellicum Pharmaceuticals
  • BIA Separations
  • Bioceltech Therapeutics
  • Biogen
  • BioMarin Pharmaceutical
  • BioNTech Innovative Manufacturing Services
  • Bio-Rad
  • BioReliance
  • Bioverativ
  • Biovian
  • BioVision
  • Blue Sky BioServices
  • bluebird bio
  • Brammer Bio
  • Bristol-Myers Squibb
  • Carina Biotech
  • CARsgen Therapeutics
  • Castle Creek Pharmaceuticals
  • Celgene
  • Cell Biolabs
  • Cellectis
  • CELLforCURE
  • CellGenTech
  • Cellular Biomedicine
  • Celonic
  • Celyad
  • Centre for Process Innovation
  • CEVEC Pharmaceuticals
  • China Immunotech
  • Clean Cells
  • Cobra Biologics
  • Cold Genesys
  • Creative Biogene
  • Creative Biolabs
  • CRISPR Therapeutics
  • Cytiva
  • Cytovance Biologics
  • Daiichi Sankyo
  • DNAtrix
  • Editas Medicine
  • Emergent BioSolutions
  • Epeius Biotechnologies
  • Errant Gene Therapeutics
  • Esteve
  • ExcellGene
  • Fibrocell
  • FinVector
  • FIT Biotech
  • FKD Therapies
  • Flash Therapeutics
  • Flexion Therapeutics
  • Formula Pharmaceuticals
  • Fosun Pharma
  • Freeline Therapeutics
  • FUJIFILM Diosynth Biotechnologies
  • GE Healthcare
  • GEG Tech
  • Gene Biotherapeutics  
  • GeneCure Biotechnologies
  • GeneDetect
  • Genelux Corporation
  • Genethon
  • Genezen Laboratories
  • GenIbet Biopharmaceuticals
  • GenSight Biologics
  • GenVec
  • GlaxoSmithKline
  • Gracell Biotechnologies
  • Guangdong Xiangxue Precision Medical Technology
  • Guangdong Zhaotai InVivo Biomedicine
  • Guangzhou Anjie Biomedical Technology
  • Guangzhou Double Bioproducts
  • Guangzhou FineImmune Biotechnology
  • Guangzhou YiYang Biological Technology
  • Gyroscope Therapeutics
  • Hebei Senlang Biotechnology
  • Hemera Biosciences
  • Henan Hualong Biotechnology Company
  • Herantis Pharma
  • Holostem Terapie Avanzate
  • Homology Medicines
  • Horama
  • Hrain Biotechnology
  • Hunan Zhaotai Yongren Biotech
  • Hunan Zhaotai Yongren Medical Innovation
  • iCAR Bio Therapeutics
  • iCarTAB BioMed
  • iCell Gene Therapeutics
  • ID Pharma
  • Immatics
  • Immunocore
  • Innovative Cellular Therapeutics
  • Janssen Pharmaceuticals
  • Juno Therapeutics
  • JW Therapeutics
  • KAEDI
  • Kite Pharma
  • Kolon TissueGene
  • Krystal Biotech
  • Kuur Therapeutics
  • Lentigen Technology
  • Leucid Bio
  • Lion TCR
  • Lokon Pharma
  • Lonza
  • Lysogene
  • Marino Biotechnology
  • Marsala Biotech
  • Mayflower Bioscience
  • Medigene
  • MedImmune
  • MeiraGTx
  • Merck
  • Milo Biotechnology
  • Miltenyi Biotec
  • MingJu Therapeutics
  • MolMed
  • Momotaro-Gene
  • MultiVir
  • Mustang Bio
  • Myonexus Therapeutics
  • Nanjing Legend Biotech
  • NEC
  • Neuralgene
  • Neurocrine Biosciences
  • Nightstar Therapeutics
  • Nikon CeLL innovation
  • Norgen Biotek
  • Novartis
  • Novasep
  • Oncolys BioPharma
  • ORCA Therapeutics
  • Orchard Therapeutics
  • Oxford BioMedica
  • Oxford Genetics
  • OZ Biosciences
  • Pall Biotech
  • Paragon Gene Therapy
  • PeriphaGen
  • PersonGen BioTherapeutics
  • Pfizer
  • Pinze Lifetechnology
  • Precigen
  • Precision BioSciences
  • ProBioGen
  • ProMab Biotechnologies
  • PsiOxus Therapeutics
  • PTC Therapeutics
  • Regeneron Pharmaceuticals
  • REGENXBIO
  • ReiThera
  • Renova Therapeutics
  • Rocket Pharmaceuticals
  • Rubius Therapeutics
  • SAB Technology
  • Sangamo Therapeutics
  • Sanofi
  • Sarepta Therapeutics
  • Sartorius
  • Servier
  • Shanghai Bioray Laboratory
  • Shanghai GeneChem
  • Shanghai Longyao Biotechnology
  • Shanghai Sinobioway Sunterra Biotechnology
  • Shanghai Sunway Biotech
  • Shanghai Unicar-Therapy Bio-medicine Technology
  • Shenzhen BinDeBio
  • Shenzhen SiBiono GeneTech
  • Shionogi
  • SignaGen Laboratories
  • SillaJen
  • Sinobioway Cell Therapy
  • SIRION Biotech
  • Solid Biosciences
  • Sorrento Therapeutics
  • SOTIO
  • Spark Therapeutics
  • System Biosciences
  • Takara Bio
  • Takeda
  • Targovax
  • Tasly Biopharmaceuticals
  • TCR2 Therapeutics
  • TCRCure Biopharma
  • The Beijing Pregene Science and Technology
  • The Pregene (ShenZhen) Biotechnology
  • TheraBiologics
  • Theravectys
  • Thermo Fisher Scientific
  • Tianjin Mycure Medical Technology
  • Timmune
  • Tmunity Therapeutics
  • Tocagen
  • Transgene
  • Ultragenyx Pharmaceutical
  • Union Stem Cell & Gene Engineering
  • uniQure
  • Unum Therapeutics
  • Vascular Biogenics
  • VCN Biosciences
  • Vector Biolabs
  • Vertex Pharmaceuticals
  • Vessl
  • Vibalogics
  • Vigene Biosciences
  • ViralGEN
  • Virapur
  • ViraQuest
  • Virovek
  • Virttu Biologics
  • VIVEbiotech
  • Voyager Therapeutics
  • Wuhan Sian Medical Technology
  • WuXi AppTec
  • Wyvern Pharmaceuticals
  • Xiangxue Life Sciences
  • Xiangxue Pharmaceutical
  • XyloCor Therapeutics
  • Yake Biotechnology
  • Yposkesi
  • Ziopharm Oncology
Note: Product cover images may vary from those shown
4 of 4

 

 

Loading
LOADING...

Adroll
adroll